Abstract:RB1CC1/FIP200 is an essential macroautophagy/autophagy protein that plays an important role in a variety of biological and disease processes through its canonical autophagy-dependent and -independent functions. However, it remains largely unknown whether post-translational modifications could regulate RB1CC1 and its associated autophagy functions. Here, we report acetylation of several lysine residues of RB1CC1 by acetyltransferase CREBBP (CREB binding protein), with K276 as the major CREBBP acetylation site. K276 is also identified as a ubiquitination site by mass spectrometry, and acetylation at this site reduces ubiquitination of RB1CC1 to inhibit its ubiquitin-dependent degradation. We also find that RB1CC1 contains an N-terminal intrinsically disordered region (IDR) capable of forming liquid-liquid phase separation (LLPS) in vitro, which may drive formation of RB1CC1 puncta with LLPS properties in cells independent of SQSTM1/p62 and other autophagy receptors CALCOCO2/NDP52, NBR1, TAX1BP1 and OPTN. Mutational analysis shows that both K276 acetylation and the N-terminal IDR containing it are important for maintaining canonical autophagy function of RB1CC1 in breast cancer cells. Our findings demonstrate regulation of RB1CC1 by a new post-translational mechanism and suggest potential therapeutic application of inducing RB1CC1 degradation through blocking K276 acetylation in the treatment of cancer and other diseases. Abbreviations: Baf-A1: bafilomycin A 1 ; CREBBP/CBP: CREB binding protein; CHX: cycloheximide; EP300/p300: E1A binding protein p300; FRAP: fluorescence recovery after photobleaching; HADCs: histone deacetylases; IDR: intrinsically disordered region; LLPS: liquid-liquid phase separation; KAT2A/GCN5: lysine acetyltransferase 2A; KAT2B/PCAF: lysine acetyltransferase 2B; KAT5/TIP60: lysine acetyltransferase 5; KAT8/MOF: lysine acetyltransferase 8; NAM: nicotinamide; PAS: phagophore assembly site; PEG-8000: polyethylene glycol 8000; RB1CC1/FIP200: RB1 inducible coiled-coil 1; TSA: trichostatin A.

Akt kinase targets the association of CBP with histone H3 to regulate the acetylation of lysine K18.

Eb1 Acetylation By P300/Cbp-Associated Factor (Pcaf) Ensures Accurate Kinetochore-Microtubule Interactions In Mitosis

Distinct Roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in Nuclear Receptor Transactivation.

AMPK Regulates Autophagy by Phosphorylating BECN1 at Threonine 388.

Pten Acetylation Modulates Its Interaction With Pdz Domain

Oncogene Ras/Phosphatidylinositol 3-Kinase Signaling Targets Histone H3 Acetylation at Lysine 56

Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment

Pcaf-Primed Ezh2 Acetylation Regulates Its Stability and Promotes Lung Adenocarcinoma Progression

Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation

Polycomb inhibits histone acetylation by CBP by binding directly to its catalytic domain

The Ras-ERK signaling pathway regulates acetylated activating transcription factor 2 via p300 in pancreatic cancer cells

The Acetylation of Transcription Factor HBP1 by P300/cbp Enhances P16ink4a Expression

Acetyltransferases CBP/p300 control transcriptional switch of β‐catenin and Stat1 promoting osteoblast differentiation

AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation

Acetylation regulates the nucleocytoplasmic distribution and oncogenic function of karyopherin alpha 2 in lung adenocarcinoma

Regulation of RB1CC1/FIP200 stability and autophagy function by CREBBP-mediated acetylation in an intrinsically disordered region

Activation of AMPK inhibits cervical cancer growth by hyperacetylation of H3K9 through PCAF

LATS1 K751 Acetylation Blocks Activation of Hippo Signalling and Switches LATS1 from a Tumor Suppressor to an Oncoprotein

The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer

CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers

Acetylation-dependent regulation of BRAF oncogenic function